Prognostic Factors Associated with Survival in Breast Cancer After Curative-İntent Radiotherapy

Article Sidebar

PDF
Published: Jan 7, 2026
DOI: https://doi.org/10.47191/ijpbms/v6-i1-03
Keywords:
Breast Cancer, Curative, Radiotherapy, Prognosis

Main Article Content

Ozlem ESER KİLİNC
Department of Radiation Oncology, Etlik City Hospital, Ankara, Turkey
Orhan SEZEN
Department of Radiation Oncology, Atatürk University, Faculty of Medicine, Erzurum, Turkey
Hilal TAHİRLER
Department of Internal Medicine, Gülhane Training and Research Hospital, Ankara, Turkey
Yilmaz SAHİN
Department of Therapy and Rehabilitation, Health Services Vocational School, Ataturk University, Erzurum, Turkey

Abstract

Objective: Prognostic factors affecting mortality after external radiotherapy (RT) in breast cancer (BC) patients are still open to research. This study aims to evaluate survival factors with regional data in patients with BC who received curative-intent RT.


Methods: A single-center retrospective observational study was conducted at the Department of Radiation Oncology in a university hospital. Patients aged 18 years or older, who did not have metastasis and received RT, were included in the study. For the analysis of patient survival data, the Kaplan-Meier method was used, and the comparison of survival times based on categorizable parameters was performed using the Log-rank analysis.


Results: A total of 51 patients were included in the study. The overall survival and disease-specific survival times are 78.2+ months. The overall survival time decreased statistically significantly with the progression of T stage (p=0.038). Patients who did not develop metastases had substantially longer survival compared to those who did (p<0.001). A statistically significant difference was found in the overall survival rates of patients based on their remission and recurrence status (p<0.001).


Conclusion: T stage, presence of metastasis, and hormone therapy are the main factors affecting survival.

Article Details

How to Cite
KİLİNC, O. E. ., SEZEN, O. ., TAHİRLER, H. ., & SAHİN, Y. . (2026). Prognostic Factors Associated with Survival in Breast Cancer After Curative-İntent Radiotherapy. International Journal of Pharmaceutical and Bio Medical Science, 6(01), 647–655. https://doi.org/10.47191/ijpbms/v6-i1-03
Issue
Vol. 6 No. 01 (2026): Volume 06 Issue 01 January 2026
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer. Clin Exp Med. 2023;23(1):1-16. doi: 10.1007/s10238-021-00781-1.

II. Castaneda SA, Strasser J. Updates in the Treatment of Breast Cancer with Radiotherapy. Surg Oncol Clin N Am. 2017;26(3):371-382. doi: 10.1016/j.soc.2017.01.013.

III. Polgár C, Kahán Z, Ivanov O, Chorváth M, Ligačová A, Csejtei A, Gábor G, Landherr L, Mangel L, Mayer Á, Fodor J. Radiotherapy of Breast Cancer-Professional Guideline 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathol Oncol Res. 2022;23;28:1610378. doi: 10.3389/pore . 2022.1610378.

IV. Dai L, Cui H, Bao Y, Hu L, Zhou Z, Lin S, Zhang X, Wu H, Kang H, Ma X. Prognostic effect of radiotherapy in breast cancer patients underwent immediate reconstruction after mastectomy. Front Oncol. 2022;2;12:1010088.

doi: 10.3389/fonc.2022.1010088.

V. Overgaard J, Aznar MC, Bacchus C, Coppes RP, Deutsch E, Georg D, Haustermans K, Hoskin P, Krause M, Lartigau EF, Lee AWM, Löck S, Offersen BV, Thwaites DI, van der Kogel AJ, van der Heide UA, Valentini V, Baumann M. Personalised radiation therapy taking both the tumour and patient into consideration. Radiother Oncol. 2022;166:A1-A5.

doi: 10.1016/j.radonc.2022.01.010.

VI. García-Sancha N, Corchado-Cobos R, Pérez-Losada J. Understanding Susceptibility to Breast Cancer: From Risk Factors to Prevention Strategies. Int J Mol Sci. 2025;25;26(7):2993.

doi: 10.3390/ijms26072993.

VII. Kim J, Munster PN. Estrogens and breast cancer. Annals of Oncology. 2025;36(2):134 – 148.

VIII. Tarlan M, Khazaei S, Madani SH, Saleh E. Prognostic factors for cancer-specific survival in 220 patients with breast cancer: A single center experience. Cancer Rep (Hoboken). 2023;6(1):e1675. doi: 10.1002/cnr2.1675.

IX. Khande TA, Joshi AR, Khandeparkar SGS, Kulkarni MM, Gogate BP, Kakade AR, Sahu PD, Khillare CD. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes. Indian J Cancer. 2020;57(2):190-197.

doi: 10.4103/ijc.IJC_610_18.

X. Wieder V, Engel J, Bauer∙ M, Kaufhold S, Hanf. V, Uleer C, et al. 284P Prognostic and predictive impact of uPA/PAI-1 in early breast cancer. Annals of Oncology. 2023;34:297.

XI. Susini T, Biglia N, Bounous VE. Prognostic Factors Research in Breast Cancer Patients: New Paths. Cancers (Basel). 2022;15;14(4):971. doi: 10.3390/cancers14040971.

XII. Liu Y, He M, Zuo WJ, Hao S, Wang ZH, Shao ZM. Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement. Front Oncol. 2021;9;11:585613. doi: 10.3389/fonc.2021.585613.

XIII. Zhang M, Deng H, Hu R, Chen F, Dong S, Zhang S, Guo W, Yang W, Chen W. Patterns and prognostic implications of distant metastasis in breast Cancer based on SEER population data. Sci Rep. 2025;23;15(1):26717. doi: 10.1038/s41598-025-12883-x.

XIV. Hu M, Shao B, Ran R, Li H. Prognostic factors for patients with metastatic breast cancer: a literature review. Transl Cancer Res. 2021;10(4):1644-1655. doi: 10.21037/tcr-20-2119.

XV. Yıldırım HÇ, Üner M, Özmen TY, et al. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer. J Oncol Sci. 2023;9(1):33-37. doi:10.37047/jos.2022-94227.

XVI. Yang M, Wang Z, Xue J, Dai J, Zhu C, Qin X. Subsequent primary cancer risk and mortality among premenopausal breast cancer survivors. Sci Rep. 2025;28;15(1):10829. doi: 10.1038/s41598-024-84606-7.